MSM. Yu. Sheremet

M. Yu. Sheremet

*This is an algorithmically generated author record based on publicly available information.

M. Yu. Sheremet has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Are menses always necessary for pregnancy in patients with breast cancer?

    by M. Yu. Sheremet, A. E. Protasova, A. N. Turomsha

    A clinical case of pregnancy in a patient with breast cancer during adjuvant hormonal therapy with tamoxifen is presented. The patient underwent combined treatment: neoadjuvant chemotherapy with ovarian suppression, organpreserving surgery, radiation therapy and further hormonal therapy after the cancellation of ovarian suppression. The clinical case emphasizes the need to inform patients about the risk of pregnancy without restoration of menstrual function during tamoxifen intake and the importance of reliable contraception.

  • Open Access

    Epithelioid hemangioendothelioma of the lung: a clinical case

    by A. N. Turomsha, A. E. Protasova, M. Yu. Sheremet

    Epithelioid hemangioendothelioma (EGE) is an extremely rare vascular sarcoma characterized by unique morpho­logical and molecular features. The incidence is about 1 case per million people. This publication presents data on clinical cases with various localizations of EGE published in the Russian literature. Our unique clinical example of lung EGE is presented, which was accompanied by significant difficulties in histological verification. The paper analyzes the features of the diagnosis of this disease, as well as presents data on the treatment and its results.

  • Open Access

    Поздние осложнения противоопухолевой терапии. Фертильность. Решение проблемы

    by М. Ю. Шеремет, А. Э. Протасова

    Цель исследования: Анализ публикаций о существующих методах сохранения фертильности у пациентов репродуктивного возраста, перед проведением гонадотоксичной противоопухолевой терапии.Материал и методы: Обзор статей, опубликованных в зарубежной и отечественной литературе за последние 10 лет.Результаты: Проблема сохранения фертильности становится более актуальной с каждым годом. На сегодняшний день все чаще поднимается вопрос не только о проведении наиболее эффективного лечения онкологических заболеваний, но и о последующем качестве жизни таких пациентов. Возрастает необходимость развития методов преодоления бесплодия и их интеграцию в оказание помощи онкологическим пациентам. В данном обзоре освещены основные методы сохранения фертильности, их преимущества и недостатки, а также их место в клинической практике.Заключение: Совершенствование вспомогательных репродуктивных технологий, информирование пациентов репродуктивного возраста врачом-онкологом о возможности сохранения биологического материала перед началом противоопухолевой терапии, разработка эффективных стратегий сохранения фертильности являются ключевыми звеньями в комплексном лечении онкологических больных.

  • Open Access

    Ovarian cancer in situ: a case report

    by A. N. Turomsha, A. E. Protasova, G. A. Raskin, E. D. Kravtsova, A. L. Andreev, L. V. Strakh, M. Yu. Sheremet

    In most cases, ovarian cancer is diagnosed at advanced stages, leading to a poor prognosis. Currently, there is no effective screening for ovarian cancer, so detecting it in the early stages is a fairly successful case.


  • Open Access

    The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia

    by A. E. Protasova, A. A. Rumyantsev, M. Yu. Sheremet, A. Yu. Goryainova, М. В. Волконский, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, et al.

    Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead to long-term and delayed effects compared to chemotherapy. Estimation of long-term efficacy and quality of life are crucial when we are talking about efficacy in whole.Aim. To evaluate the long-term clinical efficacy of lenvatinib plus pembrolizumab therapy in patients with EC.Materials and methods. The study included 43 patients with stages I-IV EC with mismatch repair-proficient tumors and treatment duration of more than 9 months. We evaluated median progression-free survival, objective response, duration of treatment depending on the line of therapy, prevalence and type of adverse events, and correction regimens. Results. Lenvatinib plus pembrolizumab treatment was safe and efficacious in recurrent EC. Median of progression-free survival (patients with response or stabilization more than 9 months) is 10.2 months (95 % confidence interval 9.1-13.0), median of follow up is 9.7 (1.4-33.8) months. There were no complete responses, partial response was in 12 (28 %) patients, disease stabilization was in 31 (72 %) patients. Regarding safety, the overall rate of any-grade adverse events was 56.3 %. The most common treatment-related adverse events were fatigue (32.6 %), hypertension (23.3 %), and hypothyroidism (18.6 %). Dose reduction was performed in 22 (51.2 %) patients.Conclusion. The combination of lenvatinib plus pembrolizumab has long-term efficacy and manageable profile of safety. The presence of a significant pool of patients with durable response allows improving the survival rate of such patients in Russia.

  • Open Access

    Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia

    by A. A. Rumyantsev, A. E. Protasova, M. Yu. Sheremet, A. Yu. Goryainova, M. V. Volkonskiy, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, et al.

    Aim. To assess the efficacy and safety of lenvatinib and pembrolizumab for the treatment of mismatch repair-proficient endometrial cancer (EC) in routine clinical practice in Russia.Materials and methods. This multicenter, retrospective, cohort study included patients with recurrent and metastatic EC from 37 cancer centers in Russia treated between May 2020 and April 2023. Patients with histologically verified EC without microsatellite instability who received ≥1 course of pembrolizumab/lenvatinib therapy were included in the study. The primary endpoint was progression-free survival; the clinical characteristics of the patients were additionally analyzed, the objective response rate and the toxicity profile of therapy were assessed.Results. The study included 100 patients. Median age was 65 (30–83) years. The most common histologic tumor subtype was endometrioid adenocarcinoma (68 %); serous adenocarcinoma was diagnosed in 22 % of cases, other types of tumor – 10 % of cases. All patients had pMMR/microsatellite-stable tumors. The median progression-free survival was 7.75 months (95 % confidence interval 0.7–33.8), and a partial response to therapy was observed in 24 % of patients. Almost half of the patients (44 %) required dose reduction due to adverse events. The most common adverse events included fatigue (n = 26; 26 %), hypertension (n = 20; 20 %), and hypothyroidism (n = 14; 14 %).Conclusion. This study confirms the clinical efficacy of lenvatinib and pembrolizumab in patients with recurrent and metastatic EC without mismatch repair system deficiency (pMMR-tumors) in routine clinical practice.